Our nanoliposome platform enables us to create both untargeted (MM-398) and targeted (MM-302) liposomes, each containing different chemotherapeutic agents.


Example: MM-398 is a nanoliposomal encapsulation of irinotecan. MM-398 has demonstrated extended circulation in comparison to free irinotecan in the clinical setting. The activated form of irinotecan is SN-38, which functions by inhibiting topoisomerase I (an essential enzyme involved in DNA transcription and replication) and promoting cell death. A Phase 1 clinical trial is assessing a potential companion diagnostic for MM-398 in patients with multiple cancer types as a first step toward determining which patients would be most likely to benefit from treatment with the drug.

Example: MM-302 is an investigational, HER2-targeted, antibody drug conjugated (ADC) nanoliposomal encapsulation of doxorubicin. MM-302 is specifically designed to allow for the selective uptake of drug into tumor cells overexpressing HER2 while limiting exposure to healthy tissues, such as the heart. MM-302 is currently being studied in a Phase 2 trial in patients with HER2-positive metastatic breast cancer.